X0M Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XOMA Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.00 |
| 52 Week High | US$23.40 |
| 52 Week Low | US$20.00 |
| Beta | 0.57 |
| 1 Month Change | 0% |
| 3 Month Change | 0.88% |
| 1 Year Change | 5.50% |
| 3 Year Change | 13.86% |
| 5 Year Change | n/a |
| Change since IPO | 14.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| X0M | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.6% |
| 1Y | 5.5% | -23.7% | 5.4% |
Return vs Industry: X0M exceeded the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: X0M matched the German Market which returned 5.4% over the past year.
Price Volatility
| X0M volatility | |
|---|---|
| X0M Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: X0M has not had significant price volatility in the past 3 months.
Volatility Over Time: X0M's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | www.xoma.com |
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Corporation Fundamentals Summary
| X0M fundamental statistics | |
|---|---|
| Market cap | €275.56m |
| Earnings (TTM) | -€41.60m |
| Revenue (TTM) | €5.36m |
51.4x
P/S Ratio-6.6x
P/E RatioIs X0M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X0M income statement (TTM) | |
|---|---|
| Revenue | US$5.81m |
| Cost of Revenue | US$122.00k |
| Gross Profit | US$5.69m |
| Other Expenses | US$50.77m |
| Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 97.90% |
| Net Profit Margin | -775.86% |
| Debt/Equity Ratio | 146.6% |
How did X0M perform over the long term?
See historical performance and comparison